Navigation Links
Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
Date:7/22/2009

s at all doses evaluated. The highest titers were observed with vaccine formulations that contained an aluminum-based adjuvant. Following vaccination, mice were exposed to live RSV through the nose. Even without adjuvant, the lowest dose (1.0 mcg) of RSV-F vaccine prevented RSV infection in the lungs of these mice. However, protection from RSV infection was not observed in unvaccinated mice. Based on these favorable pre-clinical data obtained with this RSV-F vaccine candidate and the ability to produce it at commercial yields, the Company has selected it for advanced preclinical development.

Today, the only therapy against RSV disease is a monoclonal F antibody. The antibody reduces RSV-related hospitalizations in infants and young children at high risk of severe disease. However, several injections are required and the lifespan of the antibody in the body has a limited duration. Therefore, a vaccine that induces long lasting protection against RSV-F would be highly desired by healthcare providers. There is currently no approved vaccine for the prevention of RSV and the market potential for such a vaccine could exceed $1 billion annually.

Dr. Penny Heaton, Chief Medical Officer and Vice President of Development at Novavax, stated: "A vaccine against the RSV-F protein is an ideal candidate to progress into advanced preclinical testing. Studies of the monoclonal RSV-F antibody show it protects against hospitalizations for severe RSV disease, suggesting that a vaccine which induces neutralizing antibody against RSV-F has the potential to be a powerful weapon against this disease."

ABOUT RESPIRATORY SYNCYTIAL VIRUS

RSV is the most commonly identified cause of lower respiratory tract illnesses in infants and young children. Repeated infections occur throughout life causing moderate to severe cold-like symptoms. More severe lower respiratory tract disease is also seen in elderly a
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances
2. Novavax Announces Repayment of $5 Million of Convertible Debt
3. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
4. Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain
5. Novavax Appoints Stanley Erck to Board of Directors
6. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
7. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
8. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
9. Novavax Reports First Quarter 2009 Financial Results
10. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
11. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013 The new Public-Private ... at the association’s recent annual meeting drew praise ... Vice-President Neelie Kroes, who called the action “a huge ... a stimulant to European innovation.” , The Board of ... the new Photonics PPP at its 29 April meeting ...
(Date:5/17/2013)... 17, 2013  Cellular Biomedicine Group (OTCQB: CBMG) ... of the total projected enrollment required for its ... preliminary efficacy of the medical technology haMPC (Human ... (KOA). To date the trial has had no ... Phase I open label clinical research trial for ...
(Date:5/17/2013)...  Insero Health, Inc., a company developing natural compounds ... neurological disorders, is today reporting top-line results from a ... patients with drug-resistant epilepsy.  The data are being presented ... meeting by Dr. Steven Schachter , ... Advisory Board.  In this study, INS001 appeared safe and ...
(Date:5/17/2013)... Frederick, MD (PRWEB) May 17, 2013 ... release of ezColony version 4.1, a versatile refinement ... world-class premier software solution, improves its advanced methodical ... animal facilities with ezColony 4.1. The network-based platform ... to conduct effective research. While continuing to emphasize ...
Breaking Biology Technology:SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2
... April 27 Cellectricon, a leading,provider of ... announced,its collaboration with BioFocus DPI, a contract ... screening. BioFocus DPI will utilize,Cellectricon,s Dynaflow(R)HT, a ... increase its electrophysiology-based screening capacity, particularly,for fast ...
... SALEM, Mass., April 27 LaVoie Group, a life ... been selected as investor relations agency of record for ... of LaVoie Group, commented, "Pegasus has the opportunity to ... The Company is changing the standard of care ...
... MISSISSAUGA, ON, April 24 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ: ... will succeed Terrance H. Gregg as Chairman of its Board ... Gregg,s resignation from Vasogen,s Board is due to the requirements ... , Dr. Smith, a Vasogen Board member since 1998, is ...
Cached Biology Technology:Cellectricon and BioFocus DPI Advance High Throughput ion Channel Drug Discovery 2LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster 2Vasogen Appoints Dr. Eldon Smith Chairman 2Vasogen Appoints Dr. Eldon Smith Chairman 3
(Date:5/17/2013)... proteins in the brain responsible for protecting nerve cells ... increase cell survival. , The discovery, made by researchers ... the EMBO journal with additional comment in ... stroke and other brain diseases. , The research builds ... protein, known as SUMO, responsible for controlling the chemical ...
(Date:5/17/2013)... Dartmouth College study finds human-caused climate change may ... lizards, contradicting a host of recent studies that ... planet. , The findings, which appear in the ... hope for survival of a creature thought to ... that tropical cold-blooded animals, especially forest lizards, will ...
(Date:5/16/2013)... 17, 2013) Illustrating a commitment to the ... Gastroenterological Association (AGA) Research Foundation has announced the ... Fellowship Award recipients. Supported by the National Institute ... this new award helps underrepresented minority students to ... nutrition research. , "By establishing this new award, ...
Breaking Biology News(10 mins):SUMO wrestling cells reveal new protective mechanism target for stroke 2Climate change may have little impact on tropical lizards 2Underrepresented minority students receive fellowships in digestive disease and nutrition research 2
... 18, 2007)Researchers at The University of Texas Medical School ... glucose metabolism and spina bifida. The decade-long study looked ... their children with that birth defect. UT Medical ... take part in glucose metabolism to look for a ...
... 400 grizzly bears are stored at Montana State University, waiting ... Ecosystem. Ranging from pale blond to almost black, the ... is minus-77.8 degrees. Some of the tufts are almost 25 ... a few months to be analyzed at Wildlife Genetics International ...
... Developing fetuses are extremely sensitive to radiation, which ... of screening or treatment for cancer. Now researchers from ... modeling tools that could enable safer, more accurate, and ... for pregnant women. Radiation is a doubled-edged sword: ...
Cached Biology News:UT-Houston's Northrup and colleagues uncover genetic link to spina bifida 2Study of bear hair will reveal genetic diversity of Yellowstone's grizzlies 2Safer, more accurate radiation therapy for expecting mothers 2Safer, more accurate radiation therapy for expecting mothers 3
XEDAR Antibody...
Pharmalyte, narrow range pH 4.2-4.9, 25 ml. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Immobiline for IEF and Carrier Ampholytes....
...
...
Biology Products: